Strategic Acquisition Capitalize on the May 2025 acquisition by Castle Biosciences to position Previse’s esophageal cancer screening as a complementary or feeder test within Castle’s existing diagnostic portfolio, pursuing integration discussions with Castle’s commercial channels and payer strategies.

NIH Validation Leverage the NIH grant and federal funding credibility to approach larger biopharma, diagnostics developers, and academic partnerships for co-development, validation studies, and potential co-marketing opportunities that expand reach and credibility.

Clinical Adoption Target health systems and integrated delivery networks for pilot programs of the non-invasive esophageal cancer screening test to demonstrate cost-savings and earlier intervention, using the current emphasis on value-based care to drive payer acceptance.

Go-to-Market Readiness Highlight recent seed success and LDT launch to prospective investors and strategic partners, emphasizing regulatory and commercial readiness, while proposing collaborations with diagnostic distributors and laboratory networks to expedite market entry.

Funding Leverage Use the $8.1M total funding and recent NIH grant as a proof point to secure partnerships with larger diagnostics firms, CROs, and contract manufacturers, aligning on co-development, manufacturing scale-up, and joint go-to-market plans.